Effects of Enalodustat on Heart Failure Patients with Renal Anemia

Prospective Observational Study of Enalodustat in Heart Failure Patients with Renal Anemia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041240013

Enrollment

Registered

2024-04-10

Start date

2024-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.NYHA II or III 2.eGFR 60mL/min/1.73m2 3.BNP 100 pg /mL or NT pro BNP 600 pg /mL 4.Ferritin/TSAT>100ng/mL and 20%

Exclusion criteria

Exclusion criteria: (1) Patients with any of the following Patients with malignant tumors Patients on immunosuppressive drugs Patients on immunosuppressive drugs Patients on dialysis (ii) Other research subjects who are deemed inappropriate for the safe conduct of this study by the principal investigator or physician in charge.

Design outcomes

Primary

Measure	Time frame
Calculate the 95% confidence interval for the percentage of patients achieving an Hb concentration between 10.0 g/dL and 12.0 g/dL for the evaluation period.	—

Secondary

Measure	Time frame
Echocardiographic evaluation (measurement items LVEF left ventricular myocardial weight) Cardiac markers BNP, NT pro BNP Renal markers Urine-FABP, urine NAG, urine b2-microglobulin, urine protein, serum creatinine, eGFR Anemia markers Hemoglobin, serum iron, transferrin, TIBC, TSAT, ferritin, MCV/MCH/MCHC, hepcidin Exploratory markers PGC1a , PINK1 , Parkin , PKM2	—

Contacts

Public ContactAkira Mima

Nagap Hospital

akira.mima@ompu.ac.jp+81-59-228-5181

Outcome results